(Q34757699)

4 August 2017

1 reference

title

Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? (English)

1 reference

4 August 2017

Marc Evans

1

1 reference

4 August 2017

Alan Rees

series ordinal

2

1 reference

4 August 2017

language of work or name

1 reference

1 January 2002

1 reference

4 August 2017

1 reference

4 August 2017

25

1 reference

4 August 2017

649-663

1 reference

4 August 2017

9

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-200225090-00004

4 August 2017

0 references

cites work

Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans

1 reference

12 December 2020

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

12 December 2020

Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions

1 reference

12 December 2020

In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes

1 reference

12 December 2020

Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin

1 reference

12 December 2020

Binding of drugs to human muscle

1 reference

12 December 2020

Learning from the cerivastatin experience

1 reference

12 December 2020

Metabolic causes of recurrent rhabdomyolysis

1 reference

12 December 2020

Combined treatment with specific ligands for PPARgamma:RXR nuclear receptor system markedly inhibits the expression of cytochrome P450arom in human granulosa cancer cells

1 reference

12 December 2020

Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences

1 reference

12 December 2020

Statin-fibrate combination therapy

1 reference

12 December 2020

Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy

1 reference

12 December 2020

Coronary risk factors, endothelial function, and atherosclerosis: a review

1 reference

12 December 2020

Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin

1 reference

12 December 2020

Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia

1 reference

12 December 2020

Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up

1 reference

12 December 2020

Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials

1 reference

12 December 2020

Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on human gut mucosa

1 reference

12 December 2020

Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?

1 reference

12 December 2020

Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.

1 reference

12 December 2020

Statins and risk of polyneuropathy: a case-control study

1 reference

12 December 2020

Atorvastatin calcium: an addition to HMG-CoA reductase inhibitors

1 reference

12 December 2020

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up

1 reference

12 December 2020

Polymyositis associated with simvastatin

1 reference

12 December 2020

A disorder of muscle lipid metabolism and myoglobinuria. Absence of carnitine palmityl transferase

1 reference

12 December 2020

Pharmacokinetic interaction between isradipine and lovastatin in normal, female and male volunteers

1 reference

12 December 2020

Acute Muscular Syndrome Associated with Administration of Clofibrate

1 reference

12 December 2020

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia

1 reference

12 December 2020

Drug-induced myopathies in man

1 reference

12 December 2020

Enhancement of membrane fluidity in cholesterol-poor endothelial cells pre-treated with simvastatin

1 reference

12 December 2020

In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s

1 reference

12 December 2020

Cerivastatin, a New Potent Synthetic HMG Co-A Reductase Inhibitor: Effect of 0.2 mg Daily in Subjects With Primary Hypercholesterolemia

1 reference

12 December 2020

Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations

1 reference

12 December 2020

Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent

1 reference

12 December 2020

Rhabdomyolysis, acute renal failure and hepatopathy induced by lovastatin monotherapy

1 reference

12 December 2020

Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia

1 reference

12 December 2020

Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil

1 reference

12 December 2020

Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])

1 reference

12 December 2020

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

12 December 2020

Long-Term Epidemiologic Prediction of Coronary Disease

1 reference

12 December 2020

Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease

1 reference

12 December 2020

The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day

1 reference

12 December 2020

Interaction of the peroxisome proliferator-activated receptor alpha with the retinoid X receptor alpha unmasks a cryptic peroxisome proliferator response element that overlaps an ARP-1-binding site in the CYP4A6 promoter

1 reference

12 December 2020

Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients

1 reference

12 December 2020

Changes in population cholesterol levels and coronary heart disease deaths in seven countries.

1 reference

12 December 2020

HMG-CoA reductase inhibitors and myotoxicity

1 reference

12 December 2020

Influence of cholesterol lowering on plasma membrane lipids and cationic transport systems

1 reference

12 December 2020

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor

1 reference

12 December 2020

Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

1 reference

12 December 2020

Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events

1 reference

12 December 2020

MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience

1 reference

12 December 2020

Metabolism of the new immunosuppressor cyclosporin G by human liver cytochromes P450

1 reference

12 December 2020

Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety

1 reference

12 December 2020

Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate

1 reference

12 December 2020

Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors

1 reference

12 December 2020

Is a mechanical or a metabolic approach superior in the treatment of coronary disease? Results of the atorvastatin versus revascularization (AVERT) trial

1 reference

12 December 2020

Electrical myotonia of rabbit skeletal muscles by HMG-CoA reductase inhibitors

1 reference

12 December 2020

Does differing metabolism by cytochrome p450 have clinical importance?

1 reference

12 December 2020

Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity

1 reference

12 December 2020

Rhabdomyolysis from high-dose cerivastatin therapy

1 reference

12 December 2020

Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin

1 reference

12 December 2020

Cerivastatin gender effect: sub-analyses of results from a multinational, randomised, double-blind study. Cerivastatin Study Group

1 reference

12 December 2020

Plasma concentrations of active simvastatin acid are increased by gemfibrozil

1 reference

12 December 2020

Pravastatin-Associated Inflammatory Myopathy

1 reference

12 December 2020

Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia

1 reference

12 December 2020

Lovastatin decreases plasma and platelet cholesterol levels and normalizes elevated platelet fluidity and aggregation in hypercholesterolemic patients

1 reference

12 December 2020

Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression

1 reference

12 December 2020

The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis

1 reference

12 December 2020

Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans

1 reference

12 December 2020

Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)

1 reference

12 December 2020

Rhabdomyolysis after taking atorvastatin with gemfibrozil

1 reference

12 December 2020

The pathogenesis of atherosclerosis: a perspective for the 1990s

1 reference

12 December 2020

PPAR gamma and the treatment of insulin resistance

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Reduction of plasma cholesterol by lovastatin normalizes erythrocyte membrane fluidity in patients with severe hypercholesterolaemia

1 reference

12 December 2020

Severe rhabdomyolysis and cerivastatin-gemfibrozil combination therapy

1 reference

12 December 2020

Mitochondria in neuromuscular disorders

1 reference

12 December 2020

Pravastatin-induced rhabdomyolysis in a patient with mixed connective tissue disease

1 reference

12 December 2020

Comparative tolerability of the HMG-CoA reductase inhibitors

1 reference

12 December 2020

Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety

1 reference

12 December 2020

Clinical pharmacokinetics of cerivastatin

1 reference

12 December 2020

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

1 reference

12 December 2020

10.2165/00002018-200225090-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

4 August 2017

0 references

1 reference